Abstract: Invented are methods of treatment using novel forms of paroxetine hydrochloride anhydrate.

Abstract: Invention is a method of treating cough in a mammal, including a human, which comprises administering to such mammal an effective amount of an inhibitor of GABA uptake.

Abstract: This invention relates to the use of paroxetine or a pharmaceutically acceptable salt thereof for the treatment of post-traumatic stress disorder and depression associated with withdrawal from heroin abuse.

Abstract: The invention relates to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.

Abstract: Invented is an improved process for preparing aromatic ring-fused cyclopentane derivatives. Preferred compounds prepared by this invention are indane carboxylates and cyclopentano[b]pyridine derivatives. The most preferred compounds prepared by this invention are (+)(1S, 2R, 3S)-3-[2-(2-hydroxyeth-1-yloxy)4-methoxyphenyl]-1-(3,4-methylenedioxypheny l)-5-(prop-1-yloxy)indane-2-carboxylic acid and pharmaceutically acceptable salts thereof and (+)(1S, 2R, 3S)-3-(2-carboxymethoxy-4-methoxyphenyl)-1-(3,4-methylenedioxyphenyl)-5-(p rop-1-yloxy)indane-2-carboxylic acid and pharmaceutically acceptable salts thereof. Also invented are novel intermediates useful in preparing these compounds.

Abstract: Invented is a novel pharmaceutical composition containing Paroxetine.

Abstract: Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.

Abstract: Aminophosphonates alpha substituted by phenol groups of formula (I) have lipoprotein(a) lowering activity.

Abstract: Compounds of formula (I) in which: R.sup.1 is hydrogen or an organic substituent group; R.sup.2 is a fused bicyclic heterocyclic ring system of general formula (a) wherein R.sup.4 and R.sup.5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is 0, 1 or 2; and R.sup.3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol .dbd./.dbd.

Abstract: Invented is a novel pharmaceutical composition containing Paroxetine.

Abstract: An apparatus (9) for testing the efficiency of a thermal oxidizer (200) is described. The apparatus provides for a test chemical to be directed into a thermal oxidizer so that the entry and exit flow rates of test chemical through the termal oxidizer may be accurately measured. In a portable version, the apparatus is formed of a platform (10), a tank (26) for holding liquid test chemical to test chemical vapor, and a device (94) to measure the flow rate that liquid test chemical enters the vaporizer from the tank. Methodology employing the apparatus, which provides numerical data useful in determining the efficiency of a thermal oxidizer, is described.

Abstract: Compounds of formula (I) in which R.sup.1 and R.sup.2, which may be the same or different, is each selected from hydrogen, halogen or C.sub.(1-8) alkyl; R.sup.3 is aryl or aryl C.sub.(1-4) alkyl which may be optionally substituted; X is a linker group; Y is an optionally substituted aryl group; and n is 0, 1 or 2; are inhibitors of the enzyme Lp-PLA.sub.2 and thereof of use in treating atherosclerosis.

Abstract: Described herein are substituted 2,5-Diimino-3a,6a-diaryl-1,2,3,3a,4,5,6,6a-octahydroimidazo[4,5-d]imidazol es of formula (I), wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined therein, pharmaceutical compositions containing these compounds, methods of using these compounds as G-CSF Mimetics, and processes used in preparing these compounds.

Abstract: The invention relates to novel heterocyclic compounds of formula (I) or a salt or N-oxide thereof, in which R is a group of formulae (i), (ii) or (iii), where R.sup.1 is hydrogen, halogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, COC.sub.1-6 akyl, C.sub.1-6 alkoxy, hydroxy, hydroxyC.sub.1-6 alkyl, hydroxyC.sub.1-6 alkoxy, C.sub.1-6 alkoxyC.sub.1-6 alkoxy, acyle, nitro, trifluoromethyl, cyano, SR.sup.9, SOR.sup.9, SO.sub.2 R.sup.9, NR.sup.9 CONR.sup.10 R.sup.11, NR.sup.10 SO.sub.2 R.sup.11, SO.sub.2 NR.sup.11 r.sup.11, SO.sub.2 NR.sup.10 R.sup.11, CO.sub.2 R.sup.10, CONR.sup.10 R.sup.11, CO.sub.2 NR.sup.10 R.sup.11, CONR.sup.10 (CH.sub.2).sub.a CO.sub.2 R.sup.11, (CH.sub.2).sub.a NR.sup.10 R.sup.11, ##STR1## (CH.sub.2).sub.a CONR.sup.10 R.sup.11, (CH.sub.2).sub.a COR.sup.11, (CH.sub.2).sub.a CO.sub.2 C.sub.1-6 alkyl, CO.sub.2 (CH.sub.2).sub.a OR.sup.10, NR.sup.10 R.sup.11, N.dbd.CNR.sup.9 NR.sup.10 R.sup.11, NR.sup.10 CO(CH.sub.2).sub.a NR.sup.10 R.sup.11, NR.sup.10 CO.sub.2 R.sup.11, CONHNR.sup.10 R.sup.11, CR.

Abstract: Novel heterocyclic derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments are disclosed.

Abstract: Novel piperidine derivatives of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use as medicaments for the treatment of CNS disorders are disclosed.

Abstract: The present invention is directed to a method for the treatment of post-operative nausea and vomiting wherein granisetron is administered to a patient in need thereof.

Abstract: Novel amide derivatives of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use as medicaments are disclosed.

Abstract: The invention relates to novet Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.

Abstract: A method of treatment of nausea and vomiting is disclosed which comprises administering to a human or animal subject granisetron and an antiemetic corticosteroid.